SEOUL, June 14 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its COVID-19 antibody treatment has sharply reduced recovery time and the chance of a severe case. Celltrion announced top-line results from a global phase three clinical study of Rekirona, a pivotal part of the study to obtain more comprehensive safety [...]
SEOUL, May 10 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. has begun the global supply of its COVID-19 antibody treatment starting with Pakistan, according to the company’s affiliate on Monday. Celltrion Healthcare, which handles Celltrion’s overseas business, said it has signed a contract with a Pakistan state-run company to export 100,000 tablets of [...]
SEOUL, Feb. 20 (Korea Bizwire) — South Korean biopharmaceutical company Celltrion Inc. will supply its antibody treatment for COVID-19 without a profit margin in South Korea, its chairman has said. Celltrion’s CT-P59 won the South Korean drug safety agency’s conditional approval earlier this month, becoming the first locally made treatment for the virus. The drug [...]
SEOUL, Feb. 18 (Korea Bizwire) – Celltrion Inc. said Thursday that its anti-COVID-19 monoclonal antibody treatment has confirmed neutralizing potency against the British variant, and the South Korean pharmaceutical giant has also begun developing a neutralizing antibody cocktail treatment. CT-P59, an anti-COVID-19 monoclonal antibody treatment, won the country’s drug safety agency’s conditional approval earlier this [...]
SEOUL, Feb. 17 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. began supplying its COVID-19 antibody treatment to medical institutions in the country Wednesday. CT-P59 won the drug safety agency’s conditional approval earlier this month, becoming the first locally made treatment for COVID-19. CT-P59 will be administered to COVID-19 patients at higher risk, referring [...]
SEOUL, Feb. 5 (Korea Bizwire) — South Korea’s drug safety agency said Friday it has approved pharmaceutical giant Celltrion Inc.’s COVID-19 treatment candidate on several conditions. The conditional marketing authorization of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, marks the country’s first homegrown COVID-19 treatment. The Korean Ministry of Food and Drug Safety said CT-P59 [...]
SEOUL, Jan. 13 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its COVID-19 treatment candidate reduces recovery time and the chance of a severe case developing. It was making public clinical data on the second-phase global trial study of the CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. The firm earlier submitted [...]
SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion Inc. said Tuesday that its anti-COVID-19 monoclonal antibody treatment has shown higher treatment efficacy compared to its two rival candidates. The Korean Ministry of Food and Drug Safety is currently reviewing conditional approval of Celltrion’s CT-P59, also known as Regdanvimab, a move that could [...]
SEOUL, Dec. 18 (Korea Bizwire) — South Korean biopharmaceutical giant Celltrion Inc. said Friday it has signed an agreement worth 240 billion won (US$220 million) to supply a diagnostic kit for the novel coronavirus in the United States. Under the agreement, Celltrion’s rapid antibody diagnostic test (RDT) kit for the new coronavirus, named DiaTrust, will [...]
SEOUL, Nov. 18 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s coronavirus treatment is likely to file for emergency authorization use from local drug authorities next month, the company’s chief said Wednesday. CT-P59, anti-COVID-19 monoclonal antibody treatment, is currently undergoing a phase two clinical trial locally after successfully completing a phase one clinical trial [...]